An innovative biotech company, Tryp Therapeutics (OTC: TRYPF) is propelling its psilocybin-based portfolio through recent milestones.
Upcoming Exploration of IV Psilocin
The company has garnered approval from the Australian Human Research Ethics Committee (HREC) for a Phase 1 study on its IV-infused psilocin, TRP-8803. The open-label study, set to take place at the CMAX Phase 1 unit in Adelaide, Australia, aims to assess the safety and pharmacokinetics (PK) of a single intravenous (IV) infusion of the psychedelic in nine healthy adults.
The trial aims to determine the optimal blood levels of psilocin to achieve the targeted psychedelic state and provide valuable insights into the correlation between psilocin levels and the depth and duration of the psychedelic experience. Tryp’s CSO Dr. Jim Gilligan expressed that the study aims to meet three targets of psilocin blood levels, providing a basis for dose selection in planned Phase 2 studies. Additionally, Tryp anticipates receiving 43.5% of the study costs back in cash via Australia’s R&D rebate program, significantly reducing its cost and validating the company’s plan to redomicile to Australia and list on the ASX.
Oral Psilocybin For Abdominal Pain Related To IBS & Fibromyalgia
Tryp will soon commence a Phase 2a clinical trial on oral psilocybin TRP-8802 in patients with abdominal pain and visceral tenderness due to irritable bowel syndrome (IBS.) Conducted in partnership with Massachusetts General Hospital (MGH), the pilot study aims to assess the safety and efficacy of TRP-8802 combined with psychotherapy and is scheduled to begin dosing patients in the first half of 2024.
Meanwhile, the first patient of a Phase 2a clinical trial targeting fibromyalgia treatment has been administered TRP-8802. The trial, a collaboration between the University of Michigan and Tryp, combines oral psilocybin with psychotherapy as a potential treatment for patients with fibromyalgia. With positive results in this study, Tryp would look to continue clinical development in fibromyalgia with TRP-8803 toward providing even more favorable outcomes and relief for patients with chronic pain.
Portfolio: TRP-8802 & TRP-8803
The company’s proprietary formulation of IV-infused psilocin aims to enhance psilocybin and related compounds’ positive effects while alleviating the numerous shortcomings of its oral route. Its predecessor, synthetic oral psilocybin TRP-8802, is being used to evaluate the use of psilocybin-related compounds in certain neuropsychiatric disorders in early-stage trials. If initial efficacy is shown, TRP-8803 will be studied in future trials.
With their recent milestones, Tryp Therapeutics continues to remain at the forefront of psilocybin-based treatments, providing hope for patients suffering from conditions such as IBS and fibromyalgia.
